An Open Label Study to Determine the Long Term Safety, Tolerability and Biological Activity of SAR422459 in Patients With Stargardt's Macular Degeneration

Trial Profile

An Open Label Study to Determine the Long Term Safety, Tolerability and Biological Activity of SAR422459 in Patients With Stargardt's Macular Degeneration

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Jan 2018

At a glance

  • Drugs SAR 422459 (Primary)
  • Indications Stargardt disease
  • Focus Adverse reactions
  • Sponsors Oxford BioMedica; Sanofi
  • Most Recent Events

    • 18 Jan 2018 Planned number of patients changed from 28 to 46.
    • 21 Dec 2017 Planned End Date changed from 13 Nov 2034 to 27 Nov 2034.
    • 21 Dec 2017 Planned primary completion date changed from 13 Nov 2034 to 27 Nov 2034.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top